재조합 인간 상피성장인자의 욕창에 대한 치료 효과
Therapeutic Effect of the Recombinant Human Epidermal Growth Factor (rhEGF) in Pressure Ulcer
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: To investigate the effect of the recombinant human epidermal growth factor (rhEGF) on pressure ulcer treatment. Method: Eighteen patients who had stage 3 or 4 pressure ulcer were divided into two groups. For experimental group, we cleaned the wound with normal saline, applied 0.5 ml of EasyEF liquidⓇ (rhEGF 0.5 mg/10 ml) and covered the wound with the humidified gauze 2 times a day. For control group, we cleaned with normal saline and covered with the medifoam for 2 times a day. We estimated the change of the size and the stage of the ulcer weekly for 4 weeks. The longest region of the wound was measured by the width, and the longest line perpendicular to the width was measured by the length. Results: The width and length of the stage 3 ulcer of experimental group significantly decreased, while control group showed a slightly decreased. The experimental group showed significant improvement compared to the control group (p＜0.05) in stage 3 ulcer. In stage 4 ulcer treatment, there were no significant differences between the two groups. In experimental group, 5 regions of the six stage 3 ulcer improved into the stage 2 ulcer during the study, even though only 1 region improved into the stage 2 ulcer in control group. Conclusion: We confirmed that rhEGF was effective in the stage 3 ulcer. rhEGF treatment may be useful for healing of the stage 3 ulcers. (J Korean Acad Rehab Med 2010; 34: 253-258)
Abstract
Objective: To investigate the effect of the recombinant human epidermal growth factor (rhEGF) on pressure ulcer treatment. Method: Eighteen patients who had stage 3 or 4 pressure ulcer were divided into two groups. For experimental group, we cleaned the wound with normal saline, applied 0.5 ml of EasyEF liquidⓇ (rhEGF 0.5 mg/10 ml) and covered the wound with the humidified gauze 2 times a day. For control group, we cleaned with normal saline and covered with the medifoam for 2 times a day. We estimated the change of the size and the stage of the ulcer weekly for 4 weeks. The longest region of the wound was measured by the width, and the longest line perpendicular to the width was measured by the length. Results: The width and length of the stage 3 ulcer of experimental group significantly decreased, while control group showed a slightly decreased. The experimental group showed significant improvement compared to the control group (p＜0.05) in stage 3 ulcer. In stage 4 ulcer treatment, there were no significant differences between the two groups. In experimental group, 5 regions of the six stage 3 ulcer improved into the stage 2 ulcer during the study, even though only 1 region improved into the stage 2 ulcer in control group. Conclusion: We confirmed that rhEGF was effective in the stage 3 ulcer. rhEGF treatment may be useful for healing of the stage 3 ulcers. (J Korean Acad Rehab Med 2010; 34: 253-258)
참고문헌 (11)
- Kwon H, "Clinical observation of the pressure sore", J Korean Soc Plast Reconstr Surg, 23, pp.818~826 (1996)
- Uhm KI, "Clinical observations of pressure sore", J Korean Soc Plast Reconstr Surg, 7, pp.281~289 (1980)
- National Pressure Ulcer Advisory Panel, "Pressure ulcers in America: prevalence, incidence, and implications for the future. An executive summary of the National Pressure Ulcer Advisory Panel Monograph", Adv Skin Wound Care, 14, pp.208~215 (2001)
- Doughty D, "Management of pressure sores", J Enterostomal Ther, 15, pp.39~44 (1988)
- Kim YC, "Efficacy of hydrocolloid occlusive dressing technique in decubitus ulcer treatment: A comparative study", Yonsei Med J, 37, pp.181~185 (1996)
- Reuler JB, "The pressure sore: pathophysiology and principles of management", Ann Intern Med, 94, pp.661~666 (1981)
- Wake MC, "Pore morphology effects on the fibrovascular tissue growth in porous polymer substrates", Cell Transplant, 3, pp.339~343 (1994)
- Wikowski JA, "Histopathology of the decubitus ulcer", J Am Acad Dermatol, 6, pp.1014~1021 (1982)
- Bonassar LJ, "Interaction of epidermal growth factor and insulin-like growth factor-I in the regulation of growth plate chondrocytes", Exp Cell Res, 234, pp.1~6 (1997)
- Mohan VK, "Recombinant human epidermal growth factor (REGEN-DTM 150): Effect on healing of diabetic foot ulcers", Diabetes Res Clin Pract, 78, pp.405~411 (2007)
- Robson MC, "The role of growth factors in the healing of chronic wounds", Wound Repair Regen, 5, pp.12~17 (1997)